Table 4.
Individual or combined endpoints during the first 2 years after randomization by digoxin and placebo in subgroups of low-risk heart failurepatients in the Digitalis Investigation Group trial
| Outcomes | % (events) |
Absolute risk differencea | Hazard ratio (95% CI) | P-value | |
|---|---|---|---|---|---|
| Digoxin (n = 1201) | Placebo (n = 1224) | ||||
| Low-risk (NYHA class I–II symptoms, EF >25%, and CTR <55%) | |||||
| HF mortality or HF hospitalization | 14% (167) | 18% (216) | –4% | 0.76 (0.62–0.94) | 0.009 |
| All-cause mortality or all-cause hospitalization | 52% (623) | 49% (601) | +3% | 1.07 (0.96–1.20) | 0.221 |
| All-cause mortality | 12% (147) | 13% (158) | –1% | 0.95 (0.76–1.19) | 0.632 |
| CV mortality | 10% (119) | 9% (111) | +1% | 1.09 (0.84–1.41) | 0.512 |
| HF mortality | 3% (32) | 3% (41) | 0% | 0.80 (0.50–1.26) | 0.330 |
| All-cause hospitalization | 47% (564) | 45% (552) | +2% | 1.06 (0.94–1.19) | 0.355 |
| CV hospitalization | 33% (393) | 33% (405) | 0% | 0.98 (0.86–1.13) | 0.803 |
| HF hospitalization | 13% (155) | 17% (202) | –4% | 0.76 (0.62–0.94) | 0.009 |
| All-cause mortality or HF hospitalization | 22% (263) | 25% (307) | –3% | 0.85 (0.72–1.00) | 0.046 |
| CV mortality or HF hospitalization | 20% (240) | 22% (273) | –2% | 0.87 (0.73–1.03) | 0.110 |
CI, confidence interval; CTR, cardiothoracic ratio; CV, cardiovascular; HF, heart failure.
aAbsolute risk differences were calculated by subtracting percentage events in patients receiving placebo from those in patients receiving digoxin.